Table of Content

1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Overview
1.1 Product Overview and Scope of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
1.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Type
1.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024-2034)
1.2.2 Empagliflozin
1.2.3 Dapagliflozin
1.2.4 Canagliflozin
1.2.5 Others
1.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Segment by Application
1.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value by Application: (2024-2034)
1.3.2 Offline Retail Pharmacy
1.3.3 Hospitals and Clinics
1.3.4 E-commerce and Internet Medical Care
1.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size Estimates and Forecasts
1.4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue 2024-2034
1.4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales 2024-2034
1.4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competition by Manufacturers
2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2024-2024)
2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Manufacturers (2024-2024)
2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price by Manufacturers (2024-2024)
2.4 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
2.7 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation and Trends
2.7.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest SGLT-2 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue
2.7.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Retrospective Market Scenario by Region
3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2024-2034
3.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2024-2024
3.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2024-2034
3.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024-2034
3.3.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024-2024
3.3.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024-2034
3.4 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.4.1 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.4.3 North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.5.1 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.5.3 Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.6.3 Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.7.1 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.7.3 Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034)
3.8.3 Middle East and Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2024-2034)
4.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2024-2024)
4.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2024-2034)
4.1.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2024-2034)
4.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2024-2034)
4.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2024-2024)
4.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2024-2034)
4.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2024-2034)
4.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Type (2024-2034)
5 Segment by Application
5.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2024-2034)
5.1.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2024-2024)
5.1.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2024-2034)
5.1.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2024-2034)
5.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2024-2034)
5.2.1 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2024-2024)
5.2.2 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2024-2034)
5.2.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2024-2034)
5.3 Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price by Application (2024-2034)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.1.4 AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Astellas
6.6.1 Astellas Corporation Information
6.6.2 Astellas Description and Business Overview
6.6.3 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.6.5 Astellas Recent Developments/Updates
6.7 Chugai Pharmaceutical
6.6.1 Chugai Pharmaceutical Corporation Information
6.6.2 Chugai Pharmaceutical Description and Business Overview
6.6.3 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.7.5 Chugai Pharmaceutical Recent Developments/Updates
6.8 Taisho Pharmaceutical
6.8.1 Taisho Pharmaceutical Corporation Information
6.8.2 Taisho Pharmaceutical Description and Business Overview
6.8.3 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.8.5 Taisho Pharmaceutical Recent Developments/Updates
6.9 Jiangsu Hengrui Medicine
6.9.1 Jiangsu Hengrui Medicine Corporation Information
6.9.2 Jiangsu Hengrui Medicine Description and Business Overview
6.9.3 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
6.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Chain Analysis
7.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
7.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales and Marketing
7.4.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Channels
7.4.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors
7.5 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers
8 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Dynamics
8.1 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Industry Trends
8.2 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Drivers
8.3 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Challenges
8.4 SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Competitive Situation by Manufacturers in 2022
Table 4. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) of Key Manufacturers (2024-2024)
Table 5. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Manufacturers (2024-2024)
Table 6. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Product Type & Application
Table 12. Global Key Manufacturers of SGLT-2 Inhibitors for Type 2 Diabetes Treatment, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in SGLT-2 Inhibitors for Type 2 Diabetes Treatment as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2024) & (M Units)
Table 18. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2024-2024)
Table 19. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2034) & (M Units)
Table 20. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2024-2034)
Table 21. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2024-2024)
Table 23. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2024-2034)
Table 25. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 27. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 28. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 32. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 33. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2024) & (M Units)
Table 37. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2024-2034) & (M Units)
Table 38. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 42. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 43. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2024) & (M Units)
Table 47. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2024-2034) & (M Units)
Table 48. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Type (2024-2024)
Table 51. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Type (2024-2034)
Table 52. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2024-2024)
Table 53. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2024-2034)
Table 54. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Type (2024-2024)
Table 55. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Type (2024-2034)
Table 56. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2024-2024)
Table 57. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2024-2034)
Table 58. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2024-2024)
Table 59. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2024-2034)
Table 60. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Application (2024-2024)
Table 61. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units) by Application (2024-2034)
Table 62. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2024-2024)
Table 63. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2024-2034)
Table 64. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Application (2024-2024)
Table 65. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue (US$ Million) by Application (2024-2034)
Table 66. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2024-2024)
Table 67. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2024-2034)
Table 68. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2024-2024)
Table 69. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2024-2034)
Table 70. AstraZeneca Corporation Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 73. AstraZeneca SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Johnson & Johnson Corporation Information
Table 76. Johnson & Johnson Description and Business Overview
Table 77. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 78. Johnson & Johnson SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 79. Johnson & Johnson Recent Developments/Updates
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 83. Boehringer Ingelheim SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Merck Corporation Information
Table 86. Merck Description and Business Overview
Table 87. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 88. Merck SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 89. Merck Recent Developments/Updates
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 93. Sanofi SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Astellas Corporation Information
Table 96. Astellas Description and Business Overview
Table 97. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 98. Astellas SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 99. Astellas Recent Developments/Updates
Table 100. Chugai Pharmaceutical Corporation Information
Table 101. Chugai Pharmaceutical Description and Business Overview
Table 102. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 103. Chugai Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 104. Chugai Pharmaceutical Recent Developments/Updates
Table 105. Taisho Pharmaceutical Corporation Information
Table 106. Taisho Pharmaceutical Description and Business Overview
Table 107. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 108. Taisho Pharmaceutical SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 109. Taisho Pharmaceutical Recent Developments/Updates
Table 110. Jiangsu Hengrui Medicine Corporation Information
Table 111. Jiangsu Hengrui Medicine Description and Business Overview
Table 112. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (M Units), Revenue (US$ Million), Price (US$/K Unit) and Gross Margin (2024-2024)
Table 113. Jiangsu Hengrui Medicine SGLT-2 Inhibitors for Type 2 Diabetes Treatment Product
Table 114. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Distributors List
Table 118. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Customers List
Table 119. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Trends
Table 120. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Drivers
Table 121. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Challenges
Table 122. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of SGLT-2 Inhibitors for Type 2 Diabetes Treatment
Figure 2. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Type in 2022 & 2034
Figure 4. Empagliflozin Product Picture
Figure 5. Dapagliflozin Product Picture
Figure 6. Canagliflozin Product Picture
Figure 7. Others Product Picture
Figure 8. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Application in 2022 & 2034
Figure 10. Offline Retail Pharmacy
Figure 11. Hospitals and Clinics
Figure 12. E-commerce and Internet Medical Care
Figure 13. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 14. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size (2024-2034) & (US$ Million)
Figure 15. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales (2024-2034) & (M Units)
Figure 16. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Average Price (US$/K Unit) & (2024-2034)
Figure 17. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Report Years Considered
Figure 18. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Share by Manufacturers in 2022
Figure 19. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest SGLT-2 Inhibitors for Type 2 Diabetes Treatment Players: Market Share by Revenue in 2022
Figure 21. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 22. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 23. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 24. North America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 25. United States SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 26. Canada SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 28. Europe SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 29. Germany SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. France SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. U.K. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Italy SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. Russia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Region (2024-2034)
Figure 35. Asia Pacific SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2024-2034)
Figure 36. China SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Japan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. South Korea SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. India SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Australia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. China Taiwan SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Southeast Asia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 44. Latin America SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 45. Mexico SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Brazil SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 47. Argentina SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Country (2024-2034)
Figure 49. Middle East & Africa SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Country (2024-2034)
Figure 50. Turkey SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. Saudi Arabia SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 52. UAE SGLT-2 Inhibitors for Type 2 Diabetes Treatment Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 53. Global Sales Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Type (2024-2034)
Figure 54. Global Revenue Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Type (2024-2034)
Figure 55. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Type (2024-2034)
Figure 56. Global Sales Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application (2024-2034)
Figure 57. Global Revenue Market Share of SGLT-2 Inhibitors for Type 2 Diabetes Treatment by Application (2024-2034)
Figure 58. Global SGLT-2 Inhibitors for Type 2 Diabetes Treatment Price (US$/K Unit) by Application (2024-2034)
Figure 59. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Value Chain
Figure 60. SGLT-2 Inhibitors for Type 2 Diabetes Treatment Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed